Tom Powles: Cisplatin or Carboplatin-Based Chemotherapy with Pembrolizumab in Advanced Urothelial Cancer
Tom Powles, Director of Barts Cancer Centre, shared a recent article on X:
“While EVP is better than platinum based chemotherapy in advanced bladder cancer, the debate whether cisplatin is much better than carboplatin goes on.
Here we show cisplatin combines a bit better with pembrolizumab than Carboplatin.
Matt Galsky maybe winning ESMOasia24.”
Authors: Thomas Powles, Tibor Csőszi, Yohann Loriot, Nobuaki Matsubara, Lajos Geczi, Susanna Y-S Cheng, Yves Fradet, Ajjai Alva, Stéphane Oudard, Christof Vulsteke, Rafael Morales-Barrera, Aude Fléchon, Seyda Gunduz, Chih-Chin Liu, Blanca Homet Moreno, Abhishek Bavle and Mustafa Özgüroğlu
Professor Thomas Powles, specializing in urology cancer, holds the position of Professor at the University of London since 2012 and serves as the Director of Barts Cancer Centre, a CRUK Major Cancer Centre.
With a role in biomarker development and drug strategies, he has secured multiple EMA and FDA approvals. His achievements include advancing front-line immune/targeted therapy combinations in RCC and immune checkpoint inhibition in bladder cancer.
More posts featuring Tom Powles.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023